RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA shot aims to shield older adults from RSV
⭐️ VACCINE ⭐️ CompletedThis study tested a new mRNA vaccine designed to protect against Respiratory Syncytial Virus (RSV) in adults aged 50 and older. Researchers wanted to see if the RSV shot was safe and effective when given by itself, or at the same time as a seasonal flu vaccine or an updated COVID…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 02, 2026 10:12 UTC
-
New RSV shot for seniors tested in major korean safety trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine designed to protect older adults from Respiratory Syncytial Virus (RSV), a common cause of serious lung infections. It involved 378 healthy Korean participants aged 60 and older, who received either the vaccine or a placebo shot. The main goals wer…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:15 UTC
-
Massive infant study tests One-Shot shield against dangerous RSV
Prevention CompletedThis study tested how well a single antibody shot (nirsevimab) protects infants from serious Respiratory Syncytial Virus (RSV) infections during their first RSV season. It involved nearly 50,000 infants to see if the shot reduced doctor visits, emergency room trips, and hospitali…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Apr 02, 2026 10:11 UTC